GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents (Q38266329)

1 September 2017

1 reference

title

GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents (English)

1 reference

1 September 2017

0 references

Jennifer M Trujillo

1

1 reference

PubMed ID

25382096

1 September 2017

Wesley Nuffer

series ordinal

2

1 reference

PubMed ID

25382096

1 September 2017

language of work or name

English

0 references

publication date

1 November 2014

1 reference

1 September 2017

1 reference

1 September 2017

34

1 reference

1 September 2017

1174-1186

1 reference

1 September 2017

11

1 reference

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

1 September 2017

1 reference

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

21 January 2018

1 reference

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

21 January 2018

1 reference

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

21 January 2018

1 reference

Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes

21 January 2018

1 reference

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs

21 January 2018

1 reference

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

Exenatide as a novel weight loss modality in patients without diabetes

21 January 2018

1 reference

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes

21 January 2018

1 reference

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

21 January 2018

1 reference

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.

21 January 2018

1 reference

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

21 January 2018

1 reference

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

21 January 2018

1 reference

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

21 January 2018

1 reference

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

21 January 2018

1 reference

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

21 January 2018

1 reference

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

21 January 2018

1 reference

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

21 January 2018

1 reference

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

21 January 2018

1 reference

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

21 January 2018

1 reference

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

21 January 2018

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1507

1 reference

1 September 2017

1 reference

PubMed ID

25382096